Integrated Pharmacophore-Guided Atom-Based 3D-QSAR, Molecular Docking, Virtual Screening, and ADMET Analysis for the Identification of Novel 1,3,4-Thiadiazole-Based Aldose Reductase Inhibitors
Aug 2026· Journal of Pharmaceutical Technology Research and Management· 0 citations
TL;DR
The results suggest that the scaffold 1,3,4-thiadiazole is a promising structural template for designing new generation aldose reductase inhibitors for diabetic complications.
Abstract
Background: Chronic diabetic complications develop through the important role of aldose reductase (AR), a key enzyme in the polyol pathway. Clearly, it is important to identify potent AR inhibitors with better PK properties for treatment of diabetes-associated complications.
Purpose: The purpose of this study was to discover novel 1,3,4-thiadiazole derivatives as aldose reductase inhibitors using an integrated computational drug discovery approach.
Methods: The dataset consisted of 30 reported 1,3,4-thiadiazole derivatives, which were analysed by the pharmacophore modelling, atom-based three-dimensional quantitative structure-activity relationship (3D-QSAR), molecular docking, structure-activity relationship (SAR) analysis, R-group enumeration, virtual screening and ADMET prediction methods. Using the best pharmacophore model (AHHRR_1), a validated 3D-QSAR model was developed, and 1,419 new derivatives were designed. These compounds were then further optimised for binding interactions and pharmacokinetic parameters with the top-ranked ones, including the designed derivative PD01.
Results: The optimised pharmacophore and 3D-QSAR models were able to recognise the crucial structural elements that are essential for AR inhibition. Activity increased with the hydrophobic and electron-withdrawing groups, while the bulky polar groups were responsible for decreased activity. Docking studies showed that compounds 04 (-10.178 kcal/mol), 01 (-10.081 kcal/mol), 02 (-10.050 kcal/mol), 10 (-9.977 kcal/mol), and 11 (-9.672 kcal/mol) exhibited stronger binding than Epalrestat (-8.182 kcal/mol). The highest docking score was obtained for PD01 (-10.605 kcal/mol), which had strong hydrogen-bond, hydrophobic, π-π stacking, π-cation and halogen-bond interactions. The ADMET analysis showed good drug-likeness and good oral absorption.
Conclusion: The integrated computational workflow has concluded that PD01 is the most promising lead candidate with excellent binding affinity, a favourable interaction pattern and desirable ADMET properties. The results suggest that the scaffold 1,3,4-thiadiazole is a promising structural template for designing new generation aldose reductase inhibitors for diabetic complications.
Pharmacophore analysis, 3D-QSAR, molecular docking, molecular docking, optimization of R-groups, and ADMET studies indicated that the 1,3,4-thiadiazole scaffold could be a promising template for designing potent α-glucosidase inhibitors.
Debarshi Mondal, Priya Devi, Shalini Sharma et al.· Journal of Pharmaceutical Te...· 0 citations
Findings suggest that PR1 and PR2 are promising candidates for advanced antidiabetic drug development, exhibiting predicted enhanced inhibitory activities and favorable pharmacokinetic and toxicological profiles.
L. Naanaai, Ikram Hanout, Md. Al-Amin et al.· Journal of the Iranian Chemi...· 0 citations
Breast cancer still ranks to be one of the primary causes of cancer-related death worldwide, underscoring the critical need for innovative targeted treatment agents with enhanced safety and efficacy. The current work examined Thienopyrimidinone-based derivatives as possible EGFR inhibitors for breast cancer treatment using an integrated computational drug discovery approach. An atom-based 3D-QSAR model was developed and statistically validated, exhibiting satisfactory predictive performance (R2 = 0.88 and Q2 = 0.55) and showed strong predictive numbers when checked contour maps. Hydrophobic and electron-withdrawing substitutions around the core scaffold were predicted to contribute significantly to biological activity. Pharmacophore modelling identified key structural features associated with EGFR inhibitory activity, including hydrophobic interactions, aromatic ring contacts, and hydrogen bond donor/acceptor sites, which facilitated ligand recognition. ADMET prediction and Lipinski's Rule of Five evaluation indicated that several designed derivatives possessed favourable predicted pharmacokinetic properties, favourable predicted pharmacokinetic properties and oral bioavailability, and satisfactory drug-likeness. Molecular docking studies against the mutant EGFR kinase domain (PDB ID: 6LUD) revealed favourable binding of the selected lead compounds within the ATP-binding site, supported by hydrogen-bonding and hydrophobic interactions. These investigations also revealed considerable hydrogen bonding, hydrophobic interactions, and target bound conformational orientation similar to that of reference compounds. A 100-ns molecular dynamics simulation of the EGFR-Mol 13 complex further demonstrated overall complex stability, with persistent protein-ligand interactions and adaptive ligand conformational behaviour. Overall, the integrated QSAR, pharmacophore modelling, molecular docking, ADMET prediction, and molecular dynamics analyses suggest that thienopyrimidinone derivatives represent promising computational lead compounds for the future design and experimental evaluation of EGFR-targeted therapies for breast cancer.
Shashikant V. Bhandari, Rutuja R. Napte, S. Patil et al.· Bioorganic chemistry (Print)· 0 citations
This study highlights natural diterpenoids and coumarin glycosides as promising scaffolds for caspase-1 inhibition and demonstrates that integrating QSAR modeling with structure-based approaches provides an efficient strategy for discovering potential anti-inflammatory drug candidates.
Yusuf Şeflekçi, Alper Yılmaz, Abdulilah Ece· Molecules· 0 citations
Several structurally novel compounds are identified as promising potential VEGFR2 inhibitors and supports the effectiveness of integrating pharmacophore modeling, QSAR analysis, molecular docking, and experimental validation for anticancer drug discovery.
O. Meziani, Samira Ait Kaki, F. Ferkous et al.· Journal of Computer-Aided Mo...· 0 citations
Serine/threonine kinase 3 (STK3) is a core kinase in the Hippo signaling pathway that regulates cell proliferation, differentiation, and apoptosis. Dysregulation of this pathway is linked to various cancers and immune disorders, emphasizing STK3 as a promising therapeutic target for diseases that involve abnormal cell growth. Despite their therapeutic relevance, only a limited number of potent STK3 inhibitors have been reported, likely due to the difficulty in designing molecules that can bind tightly to the ATP-binding site of STK3. Using the 2-(2-amino-5-phenylpyrimidin-4-yl)-5-methoxyphenol (APPP) scaffold identified through virtual screening, we discovered a series of novel, potent STK3 inhibitors with half-maximal inhibitory concentration (IC50) values as low as 3.52 nM. This was made possible through an integrated molecular design strategy that combined structure-based de novo design with a predictive 3D-QSAR model to estimate IC50 values and prioritize compounds for synthesis. This approach improved the prioritization of compounds for synthesis by enhancing binding energy discrimination beyond the limitations of scoring functions in de novo design. Strategic derivatization at four defined positions on the APPP core enhanced interactions in the ATP-binding site of STK3, resulting in 18 of the 25 synthesized derivatives exhibiting IC50 values below 100 nM. These findings are particularly significant given the scarcity of known STK3 inhibitors with comparable potency, while also indicating that 3D-QSAR modeling contributed as a complementary triage tool rather than a standalone driver of lead discovery. This advancement stems from the use of quantum-mechanically derived 3D structural alignments and the incorporation of electrostatic potential distributions as quantitative molecular descriptors. Taken together, this study establishes a robust design paradigm for the rapid development of highly potent kinase inhibitors through structure-based computational strategies.
Ahyoung Jang, Kewon Kim, Hyeonsoo Han et al.· ACS Omega· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
